Product Description:
Key Words:
Nefopam hydrochloride powder
CAS 13669-70-0
CAS 23327-57-3Â
Nefopam
Nefopam hydrochloride usages
Nefopam hydrochloride functions
What is Nefopam hydrochloride ?
Nefopam hydrochloride raw powder
Nefopam hcl
Pharmaceutical Chemicals
Nefopam hcl 1kg price
Nefopam hcl supplier
High quality Nefopam hcl
Product Name:Â
Nefopam, Nefopanhydrochloride
Nefopam hydrochloride CAS: 13669-70-0Â
Nefopam hydrochloride MF: C17H19NO
Nefopam hydrochloride MW: 253.34
Nefopam hydrochloride EINECS: 237-148-2
Nefopam hydrochloride Appearance: White or yellowish powder
Nefopam hydrochloride Packing: 25kg/Drum
Nefopam is a non-opiate analgesic commonly used for the treatment of moderate to severe pain. A case of a 37-year-old male who was found dead in the morning is presented. An autopsy was performed and femoral venous blood, heart blood, urine, and vitreous humor were submitted for toxicological analysis. A general drug screen detected the presence of nefopam, citalopram, gabapentin, amitriptyline, and paracetamol in cardiac blood. Nefopam was quantitated by high-performance liquid chromatography with diode-array detection. Nefopam was found at the following concentrations: 13.6 mg/L in unpreserved femoral blood; 14.7 mg/L in preserved (fluoride-oxalate) femoral blood; 21.2 mg/L in unpreserved cardiac blood and 4.5 mg/L in preserved vitreous. Citalopram was present at a concentration of 0.7 mg/L (femoral blood) and 0.9 mg/L (cardiac blood). Ethanol analyzed by headspace gas chromatography (GC-FID) was detected in preserved (fluoride-oxalate) vitreous (14 mg/100 mL) and preserved (fluoride-oxalate) urine 50 mg/100 mL. Death was attributed to atherosclerotic coronary artery disease and therapeutic drug toxicity.
Pharmaceutical form
Film coated, white, round tablet and marked APN on one side
Therapeutic indications
Nefopam Hydrochloride is indicated for the relief of acute and chronic pain, including post-operative pain, dental pain, musculo-skeletal pain, acute traumatic pain and cancer pain.
Posology and method of administration:
Posology
ADULTS: Dosage may range from 1Â to 3Â tablets three times daily depending on response. The recommended starting dosage is 2Â tablets three times daily.
OLDER PEOPLE: Older patients may require reduced dosage due to slower metabolism.
It is strongly recommended that the starting dose does not exceed one tablet three times daily as older people appear more susceptible to, in particular, the CNS side effects of Nefopam Hydrochloride and some cases of hallucinations and confusion have been reported in this age group.
PAEDIATRIC POPULATION: The safety and efficacy of Nefopam Hydrochloride in children under 12 years has not yet been established. No dosage recommendation can be given for patients under 12 years.
Patients with end stage renal disease might experience increased serum peak concentrations during treatment with Nefopam Hydrochloride. In order to avoid that, it is recommended the daily dose should be reduced not only for the elderly, but also for patients with terminal renal insufficiency.
Method of administration
Oral use.
Contraindications:
Nefopam Hydrochloride is contra-indicated in patients with a history of convulsive disorders and should not be given to patients taking mono-amine-oxidase (MAO) inhibitors. Nefopam Hydrochloride is contraindicated in patients with known hypersensitivity to any of the ingredients.
Special warnings and precautions for use:
The side effects of Nefopam Hydrochloride may be additive to those of other agents with anticholinergic or sympathomimetic activity. It should not be used in the treatment of myocardial infarction since there is no clinical experience in this indication. Hepatic and renal insufficiency may interfere with the metabolism and excretion of Nefopam Hydrochloride.
Nefopam should be used with caution in patients with angle closure glaucoma.
Cases of nefopam dependence and abuse have been reported with nefopam use.
Nefopam Hydrochloride should be used with caution in patients with, or at risk of, urinary retention.
Rarely a temporary, harmless pink discolouration of the urine has occurred.
Interaction with other medicinal products and other forms of interaction
Caution should be exercised when Nefopam Hydrochloride is administered concurrently with tricyclic antidepressants.
It should be noted that Nefopam Hydrochloride may interfere with some screening tests for benzodiazepines and opioids. These tests for benzodiazepines and opioids may give false positive results for patients taking Nefopam Hydrochloride.
Fertility, pregnancy and lactation
There is no evidence as to the drug safety in human pregnancy, nor is there evidence from animal work that it is free from hazard. Avoid in pregnancy unless there is no safer treatment.
Effects on ability to drive and use machines
Not applicable
Undesirable effects
Nausea, nervousness, dry mouth and light-headedness, urinary retention, hypotension, syncope, palpitations, gastrointestinal disturbances (including abdominal pain and diarrhoea), dizziness, paraesthesia, convulsions, tremor, confusion, hallucination, angioedema, and allergic reactions may occur. Less frequently, anaphylactic reactions, coma, vomiting, blurred vision, drowsiness, sweating, insomnia, headache and tachycardia have been reported.
Reporting of suspected adverse reactions:
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Overdose:
The clinical pattern of Nefopam Hydrochloride toxicity in overdose is on the neurological (coma, convulsions, hallucinations and agitation) and cardiovascular systems (tachycardia with a hyperdynamic circulation). Routine supportive measures should be taken and prompt removal of ingested drug by gastric Lavage or induced vomiting with Syrup of Ipecacuanha should be carried out. Oral administration of activated charcoal may help prevent absorption.
Convulsions and hallucinations should be controlled (eg with intravenously or rectally administered diazepam). Beta-adrenergic blockers may help control the cardiovascular complications.
Pharmacological properties:
Pharmacotherapeutic group: 4.7.1 Non-opioid analgesics and compound analgesic preparations
ATC code: N02BG06
Nefopam Hydrochloride is a potent and rapidly-acting analgesic. It is totally distinct from other centrally-acting analgesics such as morphine, codeine, pentazocine and propoxyphene.
Unlike the narcotic agents, Nefopam Hydrochloride has been shown not to cause respiratory depression. There is no evidence from pre-clinical research of habituation occurring with Nefopam Hydrochloride.
Pharmacokinetic properties
Nefopam Hydrochloride is absorbed from the gastro-intestinal tract. Peak plasma concentrations occur about 1-3 hours after oral administration. About 73% is bound to plasma proteins. It has an elimination half-life of about 4 hours. It is extensively metabolised and excreted mainly in urine. Less than 5% of a dose is excreted unchanged in the urine. About 8% of a dose is excreted via the faeces.
Our Additional info:
1. Our company is a professional raw powder factory in China for over 10 years, all powders are factory directly supplying.
2. Our products have exported to Germany, Norway, Poland, Finland, Spain, UK, France, Russia, USA, Australia, Japan, Korea and many other countries, over 100kgs each month.
3. Professional team special for package and shipment and staring on tracking code 24hours for customs pass guaranteed. 100% pass to UK, Norway, Poland, Spain, USA, Canada, Brazil; 98% pass to Germany, Russia, Australia, New Zealand.
4. Most of powders are in stock, Chargeable samples are available, Could be shipped out within 24hours.
High quality, good price, fast and safety delivery. Shipment by DHL, , FEDEX, HKEMS, UPS, etc.
Other hot sale , bulk stock now !
Dehydronandrolon
CAS: 2590-41-2
Flugestone Acetate
CAS: 2529-45-5
Methyldienedione
CAS: 5173-46-6
17-Hydroxy Progesterone
CAS: 68-96-2Â Â Â
Altrenogest
CAS: 850-52-2
Pregnenolone
CAS: 145-13-1
Megestrol Acetate
CAS: 595-33-5
Cyproterone Acetate
CAS: 427-51-0
Medroxyprogesterone 17-Acetate
CAS: 71-58-9
Levonorgestrel
CAS: 797-63-7
Diethylstilbestrol
CAS: 56-53-1
Estradiol Valerate
CAS: 979-32-8
Estriol
CAS: 50-27-1
Estradiol Benzoate
CAS: 50-50-0
Esterone
CAS: 53-16-7
Ethynyl Estradiol
CAS: 57-63-6
Mifepristone
CAS: 84371-65-3
Dienogestrel
CAS: 65928-58-7
Misoprostol
CAS: 59122-46-2
6-bromoandrostenedione
CAS: 38632-00-7
Cabergoline
CAS: 81409-90-7Â Â Â
Mebolazin
CAS: 3625-07-8
Methoxydienone
CAS: 2322-77-2
Diflorasone
CAS: 2557-49-5
Halodrol  Â
Â
Cabozantinib
CAS:849217-68-1
Sunitinib Malate
CAS:341031-54-7
Imatinib mesylate
CAS:220127-57-1
Â
CAS:184475-35-2
Lapatinib
CAS:231277-92-2
Nilotinib
CAS:641571-10-0
Telatinib
CAS:75747-14-7
Erlotinib hydrochloride
CAS:183319-69-9
Neratinib
CAS:698387-09-6
Dasatinib
CAS:302962-49-8
Bosutinib
CAS:380843-75-4
Imatinib
CAS:152459-95-5
Axitinib
CAS:319460-85-0
Erlotinib
CAS:183321-74-6
Vandetanib
CAS:443913-73-3
Dovitinib
CAS:915769-50-5
BIBW2992 DiMaleate
CAS:850140-73-7
Dasatinib monohydrate
CAS:863127-77-9
Crizotinib
CAS:877399-52-5
Lenvatinib (E7080)
CAS:417716-92-8
Nilotinib
CAS:641571-10-0
Product Description:
Key Words:
Nefopam hydrochloride powder
CAS 13669-70-0
CAS 23327-57-3Â
Nefopam
Nefopam hydrochloride usages
Nefopam hydrochloride functions
What is Nefopam hydrochloride ?
Nefopam hydrochloride raw powder
Nefopam hcl
Pharmaceutical Chemicals
Nefopam hcl 1kg price
Nefopam hcl supplier
High quality Nefopam hcl
Product Name:Â
Nefopam, Nefopanhydrochloride
Nefopam hydrochloride CAS: 13669-70-0Â
Nefopam hydrochloride MF: C17H19NO
Nefopam hydrochloride MW: 253.34
Nefopam hydrochloride EINECS: 237-148-2
Nefopam hydrochloride Appearance: White or yellowish powder
Nefopam hydrochloride Packing: 25kg/Drum
Nefopam is a non-opiate analgesic commonly used for the treatment of moderate to severe pain. A case of a 37-year-old male who was found dead in the morning is presented. An autopsy was performed and femoral venous blood, heart blood, urine, and vitreous humor were submitted for toxicological analysis. A general drug screen detected the presence of nefopam, citalopram, gabapentin, amitriptyline, and paracetamol in cardiac blood. Nefopam was quantitated by high-performance liquid chromatography with diode-array detection. Nefopam was found at the following concentrations: 13.6 mg/L in unpreserved femoral blood; 14.7 mg/L in preserved (fluoride-oxalate) femoral blood; 21.2 mg/L in unpreserved cardiac blood and 4.5 mg/L in preserved vitreous. Citalopram was present at a concentration of 0.7 mg/L (femoral blood) and 0.9 mg/L (cardiac blood). Ethanol analyzed by headspace gas chromatography (GC-FID) was detected in preserved (fluoride-oxalate) vitreous (14 mg/100 mL) and preserved (fluoride-oxalate) urine 50 mg/100 mL. Death was attributed to atherosclerotic coronary artery disease and therapeutic drug toxicity.
Pharmaceutical form
Film coated, white, round tablet and marked APN on one side
Therapeutic indications
Nefopam Hydrochloride is indicated for the relief of acute and chronic pain, including post-operative pain, dental pain, musculo-skeletal pain, acute traumatic pain and cancer pain.
Posology and method of administration:
Posology
ADULTS: Dosage may range from 1Â to 3Â tablets three times daily depending on response. The recommended starting dosage is 2Â tablets three times daily.
OLDER PEOPLE: Older patients may require reduced dosage due to slower metabolism.
It is strongly recommended that the starting dose does not exceed one tablet three times daily as older people appear more susceptible to, in particular, the CNS side effects of Nefopam Hydrochloride and some cases of hallucinations and confusion have been reported in this age group.
PAEDIATRIC POPULATION: The safety and efficacy of Nefopam Hydrochloride in children under 12 years has not yet been established. No dosage recommendation can be given for patients under 12 years.
Patients with end stage renal disease might experience increased serum peak concentrations during treatment with Nefopam Hydrochloride. In order to avoid that, it is recommended the daily dose should be reduced not only for the elderly, but also for patients with terminal renal insufficiency.
Method of administration
Oral use.
Contraindications:
Nefopam Hydrochloride is contra-indicated in patients with a history of convulsive disorders and should not be given to patients taking mono-amine-oxidase (MAO) inhibitors. Nefopam Hydrochloride is contraindicated in patients with known hypersensitivity to any of the ingredients.
Special warnings and precautions for use:
The side effects of Nefopam Hydrochloride may be additive to those of other agents with anticholinergic or sympathomimetic activity. It should not be used in the treatment of myocardial infarction since there is no clinical experience in this indication. Hepatic and renal insufficiency may interfere with the metabolism and excretion of Nefopam Hydrochloride.
Nefopam should be used with caution in patients with angle closure glaucoma.
Cases of nefopam dependence and abuse have been reported with nefopam use.
Nefopam Hydrochloride should be used with caution in patients with, or at risk of, urinary retention.
Rarely a temporary, harmless pink discolouration of the urine has occurred.
Interaction with other medicinal products and other forms of interaction
Caution should be exercised when Nefopam Hydrochloride is administered concurrently with tricyclic antidepressants.
It should be noted that Nefopam Hydrochloride may interfere with some screening tests for benzodiazepines and opioids. These tests for benzodiazepines and opioids may give false positive results for patients taking Nefopam Hydrochloride.
Fertility, pregnancy and lactation
There is no evidence as to the drug safety in human pregnancy, nor is there evidence from animal work that it is free from hazard. Avoid in pregnancy unless there is no safer treatment.
Effects on ability to drive and use machines
Not applicable
Undesirable effects
Nausea, nervousness, dry mouth and light-headedness, urinary retention, hypotension, syncope, palpitations, gastrointestinal disturbances (including abdominal pain and diarrhoea), dizziness, paraesthesia, convulsions, tremor, confusion, hallucination, angioedema, and allergic reactions may occur. Less frequently, anaphylactic reactions, coma, vomiting, blurred vision, drowsiness, sweating, insomnia, headache and tachycardia have been reported.
Reporting of suspected adverse reactions:
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Overdose:
The clinical pattern of Nefopam Hydrochloride toxicity in overdose is on the neurological (coma, convulsions, hallucinations and agitation) and cardiovascular systems (tachycardia with a hyperdynamic circulation). Routine supportive measures should be taken and prompt removal of ingested drug by gastric Lavage or induced vomiting with Syrup of Ipecacuanha should be carried out. Oral administration of activated charcoal may help prevent absorption.
Convulsions and hallucinations should be controlled (eg with intravenously or rectally administered diazepam). Beta-adrenergic blockers may help control the cardiovascular complications.
Pharmacological properties:
Pharmacotherapeutic group: 4.7.1 Non-opioid analgesics and compound analgesic preparations
ATC code: N02BG06
Nefopam Hydrochloride is a potent and rapidly-acting analgesic. It is totally distinct from other centrally-acting analgesics such as morphine, codeine, pentazocine and propoxyphene.
Unlike the narcotic agents, Nefopam Hydrochloride has been shown not to cause respiratory depression. There is no evidence from pre-clinical research of habituation occurring with Nefopam Hydrochloride.
Pharmacokinetic properties
Nefopam Hydrochloride is absorbed from the gastro-intestinal tract. Peak plasma concentrations occur about 1-3 hours after oral administration. About 73% is bound to plasma proteins. It has an elimination half-life of about 4 hours. It is extensively metabolised and excreted mainly in urine. Less than 5% of a dose is excreted unchanged in the urine. About 8% of a dose is excreted via the faeces.
Our Additional info:
1. Our company is a professional raw powder factory in China for over 10 years, all powders are factory directly supplying.
2. Our products have exported to Germany, Norway, Poland, Finland, Spain, UK, France, Russia, USA, Australia, Japan, Korea and many other countries, over 100kgs each month.
3. Professional team special for package and shipment and staring on tracking code 24hours for customs pass guaranteed. 100% pass to UK, Norway, Poland, Spain, USA, Canada, Brazil; 98% pass to Germany, Russia, Australia, New Zealand.
4. Most of powders are in stock, Chargeable samples are available, Could be shipped out within 24hours.
High quality, good price, fast and safety delivery. Shipment by DHL, , FEDEX, HKEMS, UPS, etc.
Other hot sale , bulk stock now !
Dehydronandrolon
CAS: 2590-41-2
Flugestone Acetate
CAS: 2529-45-5
Methyldienedione
CAS: 5173-46-6
17-Hydroxy Progesterone
CAS: 68-96-2Â Â Â
Altrenogest
CAS: 850-52-2
Pregnenolone
CAS: 145-13-1
Megestrol Acetate
CAS: 595-33-5
Cyproterone Acetate
CAS: 427-51-0
Medroxyprogesterone 17-Acetate
CAS: 71-58-9
Levonorgestrel
CAS: 797-63-7
Diethylstilbestrol
CAS: 56-53-1
Estradiol Valerate
CAS: 979-32-8
Estriol
CAS: 50-27-1
Estradiol Benzoate
CAS: 50-50-0
Esterone
CAS: 53-16-7
Ethynyl Estradiol
CAS: 57-63-6
Mifepristone
CAS: 84371-65-3
Dienogestrel
CAS: 65928-58-7
Misoprostol
CAS: 59122-46-2
6-bromoandrostenedione
CAS: 38632-00-7
Cabergoline
CAS: 81409-90-7Â Â Â
Mebolazin
CAS: 3625-07-8
Methoxydienone
CAS: 2322-77-2
Diflorasone
CAS: 2557-49-5
Halodrol  Â
Â
Cabozantinib
CAS:849217-68-1
Sunitinib Malate
CAS:341031-54-7
Imatinib mesylate
CAS:220127-57-1
Â
CAS:184475-35-2
Lapatinib
CAS:231277-92-2
Nilotinib
CAS:641571-10-0
Telatinib
CAS:75747-14-7
Erlotinib hydrochloride
CAS:183319-69-9
Neratinib
CAS:698387-09-6
Dasatinib
CAS:302962-49-8
Bosutinib
CAS:380843-75-4
Imatinib
CAS:152459-95-5
Axitinib
CAS:319460-85-0
Erlotinib
CAS:183321-74-6
Vandetanib
CAS:443913-73-3
Dovitinib
CAS:915769-50-5
BIBW2992 DiMaleate
CAS:850140-73-7
Dasatinib monohydrate
CAS:863127-77-9
Crizotinib
CAS:877399-52-5
Lenvatinib (E7080)
CAS:417716-92-8
Nilotinib
CAS:641571-10-0
99% Purity Mk-1775 / Mk2206 / Mk5172 Raw Powder Nefopanhydrochloride Distributor
Model NO.: 13669-70-0
Molecular Formula: C28h36o3
Molecular Weight: 420.58400
Usage: Bodybuilding
Einecs: 215-014-4
Reship Policy: Free Reship
Leading Time: Within 12 Hours After Payment
Delivery Time: 3-7 Days Door to Door
Ship Methods: EMS, TNT, FedEx, DHL, Hkems, Eub
Loss on Drying: 0.5%Max
Free Acid: 0.5%Max
Trademark: ZJY
Transport Package: Discreet Package
Specification: White Powder
Origin: China
HS Code: 229665523
Model NO.: 13669-70-0
Molecular Formula: C28h36o3
Molecular Weight: 420.58400
Usage: Bodybuilding
Einecs: 215-014-4
Reship Policy: Free Reship
Leading Time: Within 12 Hours After Payment
Delivery Time: 3-7 Days Door to Door
Ship Methods: EMS, TNT, FedEx, DHL, Hkems, Eub
Loss on Drying: 0.5%Max
Free Acid: 0.5%Max
Trademark: ZJY
Transport Package: Discreet Package
Specification: White Powder
Origin: China
HS Code: 229665523